Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

64.7K
Overview
64.7K
Special Features of Adaptive Immunity01:20

Special Features of Adaptive Immunity

3.7K
The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
3.7K
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

6.9K
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
6.9K
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

1.7K
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
1.7K
Development of Immunocompetence01:22

Development of Immunocompetence

1.2K
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
1.2K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

3.7K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
3.7K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Histone marks identify novel transcription factors that parse CAR-T subset-of-origin, clinical potential and expansion.

Nature communications·2024
Same author

Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA.

Nature communications·2018
Same author

Fully human CD19-specific chimeric antigen receptors for T-cell therapy.

Leukemia·2017
Same author

CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies.

Clinical pharmacology and therapeutics·2016
Same author

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo.

Leukemia·2015
Same author

HapMap SNP Scanner: an online program to mine SNPs responsible for cell phenotype.

Tissue antigens·2012

関連する実験動画

Updated: May 4, 2026

Functional Characterization of Regulatory Macrophages That Inhibit Graft-reactive Immunity
08:41

Functional Characterization of Regulatory Macrophages That Inhibit Graft-reactive Immunity

Published on: June 7, 2017

7.5K

細胞免疫の欠陥 - 欠陥の発見と修復

P D Greenberg1, S R Riddell

  • 1Fred Hutchinson Cancer Research Center and Departments of Medicine and Immunology, University of Washington, Seattle, WA 98195, USA. pgreen@u.washington.edu

Science (New York, N.Y.)
|July 27, 1999
PubMed
まとめ
この要約は機械生成です。

細胞免疫は,感染症と戦うために不可欠です. 免疫不全の理解の進歩と新しい細胞療法により,T細胞疾患の治療が改善されています.

さらに関連する動画

Preparation of CD4+ T Cells for Analysis of GD3 and GD2 Ganglioside Membrane Expression by Microscopy
10:00

Preparation of CD4+ T Cells for Analysis of GD3 and GD2 Ganglioside Membrane Expression by Microscopy

Published on: November 8, 2016

8.1K
Rapid Magnetic-microbead Method for Efficient Purification of Low-density Neutrophils
08:14

Rapid Magnetic-microbead Method for Efficient Purification of Low-density Neutrophils

Published on: November 11, 2025

620

関連する実験動画

Last Updated: May 4, 2026

Functional Characterization of Regulatory Macrophages That Inhibit Graft-reactive Immunity
08:41

Functional Characterization of Regulatory Macrophages That Inhibit Graft-reactive Immunity

Published on: June 7, 2017

7.5K
Preparation of CD4+ T Cells for Analysis of GD3 and GD2 Ganglioside Membrane Expression by Microscopy
10:00

Preparation of CD4+ T Cells for Analysis of GD3 and GD2 Ganglioside Membrane Expression by Microscopy

Published on: November 8, 2016

8.1K
Rapid Magnetic-microbead Method for Efficient Purification of Low-density Neutrophils
08:14

Rapid Magnetic-microbead Method for Efficient Purification of Low-density Neutrophils

Published on: November 11, 2025

620

科学分野:

  • 免疫学 免疫学とは
  • 感染症 感染症は感染症です.
  • セルラーセラピー 細胞療法

背景:

  • 細胞免疫,特にT細胞機能は,生命を脅かす感染症の予防に不可欠です.
  • 遺伝的または獲得的な免疫不全は,T細胞の機能をひどく低下させ,重度の感染症につながる.
  • 歴史的に見て,治療法は,根本的な免疫欠陥に対処するよりも,感染症の合併症を管理することに焦点を当てていました.

研究 の 目的:

  • 感染症耐性における細胞免疫の重要な役割を強調する.
  • 免疫不全の細胞および分子的基礎を理解する際の急速な進化を強調するために.
  • 免疫疾患に対する新興の分子および細胞療法の時代を紹介する.

主な方法:

  • 免疫不全に関する現在の理解のレビュー.
  • 細胞免疫を強化するための進化する技術の分析.
  • 新興治療戦略の議論.

主要な成果:

  • T細胞機能の障害は重度の感染症につながり,細胞免疫の重要性を強調しています.
  • 免疫不全の分子と細胞の基礎を理解する上で大きな進歩が示されています.
  • 新しい技術は,新しい細胞および分子療法の開発を可能にしています.

結論:

  • 細胞免疫は,宿主の感染に対する防御に不可欠です.
  • この分野は,免疫機能の欠陥を修正するための革新的な分子および細胞療法へと移行しています.
  • これらの治療法は,異常な遺伝子,T細胞喪失,およびホメオスタシスの問題に対処することを目的としており,研究から臨床応用に移行しています.